Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, dose-escalation Phase 1 study of the investigational agent, ON 013105.
In laboratory animal studies, ON 013105 has demonstrated anti-cancer activity. The purpose of
this study is to determine the highest dose of ON 013105 that can be given safely in patients
with relapsed/refractory Lymphoma or B-cell Acute Lymphocytic Leukemia (Philadelphia
chromosome negative). Patients will receive weekly 2-hour IV infusions of ON 013105 at higher
and higher doses until intolerable side effects are observed. It is important to know the
highest safe dose so additional studies can be done.